Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach

Absent proof of an overall survival benefit, new data suggesting a link between longer-term use of Celgene Corp.’s blockbuster Revlimid and secondary malignancies in multiple myeloma may encourage a cautious approach to maintenance treatment, threatening a major expansion for the drug.